The emergence of mephedrone along with other artificial cathinones has introduced challenges for lawmakers and regulatory companies tasked with controlling the proliferation of new psychoactive substances. The dynamic mother nature of synthetic drug output, coupled with the ability of chemists to switch molecular buildings to evade authorized limit